autologous lymphocytes being obtained by culturing autologous lymphocytes derived from a virally infected patient or an immunodeficient or immunosuppressed patient in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, said virally infected patient or an immunodeficient or immunosuppressed patient to be provided with said composition.

13. A method for preparing a composition for treating or preventing viral infections, said method comprising deriving autologous lymphocytes from a virally infected patient or an immunodeficient or immunosuppressed patient to be provided with said composition, and culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes.

14. A method for preventing or treating viral infections of herpes groups, said method comprising deriving autologous lymphocytes from a virally infected patient or an immunodeficient or immunosuppressed patient, culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, and administering said activated autologous lymphocytes to said patient from which said autologous lymphocytes were derived.

15. The composition according to claim 12, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

16. The composition according to claim 15, wherein a protein is added to said cell-suspended solution.

17. The composition according to claim 16, wherein said protein is human albumin.

18. The composition according to claim 12, wherein said culture medium further comprises cytokines.

19. The method according to claim 13, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

C1 cont.

20. The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21. The method according to claim 20, wherein said protein is human albumin.

22. The method according to claim 13, wherein said culture medium further comprises cytokines.

23. The method according to claim 14, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer

solution to make a cell-suspended solution, and administered to said patient.

24. The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25. The method according to claim 24, wherein said protein is human albumin.

26. The method according to claim 23, wherein said activated autologous lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

27. The method according to claim 23, wherein said culture medium further comprises cytokines.

28. The composition according to claim 12, wherein said patient is virally infected, immunodeficient or immunosuppressed due to a viral infection of herpes groups.

29. The composition according to claim 28, wherein said viral infection of herpes groups is an Epstein-Barr virus infection.

30. The method according to claim 13, wherein said patient is virally infected, immunodeficient or immunosuppressed due to a viral infection of herpes groups.